Will the Chargers WR stay hot in his Week 11 matchup vs. the Jets?
Will the Chargers WR stay hot in his Week 11 matchup vs. the Jets?
Turkish President Tayyip Erdogan's promise of a new economic era triggered a foreign-driven rally in the lira, but local investors have yet to be persuaded that policies they say have dragged on economic prospects for years will be reversed. Interviews with local portfolio managers, gold sellers and business owners suggest Erdogan's biggest challenge will be convincing Turkish individuals and companies he can turn last month's rhetoric of market-friendly reforms into reality. "There is a protective reflex", built up after years of lira depreciation, said Baris Hocaoglu, general manager of Istanbul Portfoy, which manages 7 billion lira ($900 million) of assets and recommends a "cautious stance" to clients.
A mother in Sweden has been arrested on suspicion of locking her son inside their apartment for 28 years, leaving him undernourished and with almost no teeth, police and media reports said Tuesday.
New York University Professor of Marketing and Author of 'Post Corona: From Crisis to Opportunity' Scott Galloway warns capitalism will fail without changes that make it more empathetic.
Indonesia may still pursue a plan to tax technology companies on the income they generate from the country even if G20 nations and the OECD cannot reach a deal on digital taxes, its finance minister said on Tuesday. Talks to rewrite rules for cross-border taxation, including digital taxes, led by the Organisation for Economic Cooperation and Development, stalled this year, with a new deadline for an agreement extended to 2021. Indonesia, Southeast Asia's biggest economy, has begun collecting a 10% value-added tax (VAT) since mid-2020 on digital products and services from internet-based firms, but officials had previously said it would charge a tax on income only after a global consensus was reached.
Dublin, Dec. 01, 2020 (GLOBE NEWSWIRE) -- The "Feminine Hygiene Products Market by Nature (Disposable, Reusable), Type (Sanitary Napkins, Panty Liners, Tampons, Menstrual Cups), Region (Asia Pacific, North America, Europe, Middle East and Africa, South America) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering. The feminine hygiene products market is projected to reach USD 27,737 million by 2025 from USD 20,963 million in 2020, at a CAGR of 5.8% from 2020 to 2025. Increasing the female population, rising disposable income of females, and women empowerment across the globe is expected to accelerate the growth of the feminine hygiene products market. The reusable nature segment is projected to grow at the highest CAGR during the forecast period. Based on nature, the reusable segment is projected to grow at the highest CAGR during the forecast period. Menstrual cups are considered under the reusable segment. Menstrual cups are widely used, especially in Western countries, due to their reusability. They are also durable and can last for approximately ten years. The use of reusable feminine hygiene products helps reducing waste created by the plastic, non-recyclable, and non-biodegradable materials present in disposable pads and tampons. Hence, they are considered eco-friendly products. The growth of the reusable segment can be attributed to the advantages of menstrual cups such as durability, low-cost, safety, and eco-friendliness over sanitary pads and tampons. The sanitary napkins type segment is projected to grow at the highest CAGR during the forecast period. Based on type, the sanitary napkins segment is projected to grow at the highest CAGR during the forecast period. A sanitary napkin is a type of feminine hygiene product that is worn externally, unlike tampons and menstrual cups, which are worn inside the vagina. Most women in developing countries such as India, South Africa, China, Thailand, Indonesia, among others are reluctant to use internal use feminine hygiene products such as menstrual cups and tampons and prefer sanitary napkins instead. This is a major factor driving the growth of sanitary napkins during the forecast period. Asia Pacific is projected to grow the highest CAGR in the feminine hygiene products market during the forecast period. Asia Pacific is projected to grow at the highest CAGR in the feminine hygiene products market from 2020 to 2025. The high growth can be attributed to the increase in government initiatives toward period poverty and menstrual hygiene management along with rapid urbanization in countries such as China, India, Japan, Indonesia, Malaysia, and Thailand. According to the World Economic Forum, 2019, one-third of the total number of girls in South Asia miss school during their periods, often because they lack access to menstrual health products and receive little or no education about menstruation before reaching puberty. The local governments are making various efforts to tackle this issue. For instance, the government of India reduced GST on menstrual hygiene products from 12% to 0% in 2018.Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 4.1 Overview of the Feminine Hygiene Products Market 4.2 Feminine Hygiene Products Market, by Region 4.3 Asia-Pacific Feminine Hygiene Products Market, by Type and Country 4.4 Feminine Hygiene Products Market, by Major Countries 5 Market Overview 5.1 Introduction 5.1.1 Drivers 220.127.116.11 Increasing Female Population & Rapid Urbanization 18.104.22.168 Rising Female Literacy and Awareness of Menstrual Health & Hygiene 22.214.171.124 Rising Disposable Income of Females and Women Empowerment 5.1.2 Restraints 126.96.36.199 Social Stigma Associated with Menstruation and Feminine Hygiene Products 5.1.3 Opportunities 188.8.131.52 Developing Eco-Friendly Feminine Hygiene Products 184.108.40.206 Growth Opportunities in Emerging Countries 5.1.4 Challenges 220.127.116.11 Impact of Feminine Hygiene Products on the Environment 18.104.22.168 Lack of Facilities for Menstrual Hygiene Management 22.214.171.124 Supply Chain, Trade, and Economic Disruptions Due to the COVID-19 Pandemic 5.2 Porter's Five Forces Analysis 5.2.1 Bargaining Power of Suppliers 5.2.2 Threat of New Entrants 5.2.3 Threat of Substitutes 5.2.4 Bargaining Power of Buyers 5.2.5 Intensity of Rivalry 6 Industry Trends 6.1 Macroeconomic Indicators 6.1.1 Female Literacy Rate 6.1.2 Human Development Index (HDI) 6.1.3 Urbanization 6.1.4 Per Capita Income 6.2 Value Chain Analysis 6.2.1 Prominent Companies 6.2.2 Small & Medium Enterprises 6.3 Raw Material Analysis 6.3.1 Superabsorbent Polymer (Sap) 6.3.2 Polypropylene (Pp) 6.3.3 Polyethylene (Pe) 6.3.4 Medical Grade Silicone 6.4 Average Selling Price Trend Analysis 6.5 Regulatory Landscape 6.6 COVID-19 Impact 6.6.1 Introduction 6.6.2 COVID-19 Health Assessment 6.6.3 COVID-19 Economic Assessment 126.96.36.199 COVID-19 Impact on the Economy-Scenario Assessment 6.7 Impact of COVID-19 on Feminine Hygiene Products Market 7 Feminine Hygiene Products Market, by Distribution Channel 7.1 Introduction 7.2 Supermarket & Hypermarket 7.2.1 COVID-19 Impact on Supermarket & Hypermarket 7.3 E-Commerce 7.3.1 COVID-19 Impact on E-Commerce 7.4 Department Store 7.5 Convenience Store 7.6 Retail Pharmacies 8 Feminine Hygiene Products Market, by Nature 8.1 Introduction 8.1.1 Disposable 8.1.2 Reusable 9 Feminine Hygiene Products Market, by Type 9.1 Introduction 9.2 Sanitary Napkins 9.3 Tampons 9.4 Panty Liners 9.5 Menstrual Cups 10 Feminine Hygiene Products Market, by Region 10.1 Introduction 10.2 Asia-Pacific 10.3 North America 10.4 Europe 10.5 South America 10.6 Middle East & Africa 11 Competitive Landscape 11.1 Overview 11.2 Market Evaluation Framework 11.3 Market Share Analysis 11.3.1 Market Share Analysis of Top Players in Feminine Hygiene Products Market 11.3.2 Revenue Analysis of Top 5 Market Players in Feminine Hygiene Products Market 11.4 Key Market Developments 12 Company Evaluation Matrix and Company Profiles 12.1 Company Evaluation Quadrant Matrix Definitions and Methodology, 2019 12.1.1 Star 12.1.2 Emerging Leaders 12.1.3 Pervasive 12.1.4 Participants 12.2 Competitive Benchmarking 12.2.1 Strength of Product Portfolio 12.2.2 Business Strategy Excellence 12.3 Company Profiles 12.3.1 Procter & Gamble 12.3.2 Kimberly-Clark Corporation 12.3.3 Johnson & Johnson 12.3.4 Unicharm Corporation 12.3.5 Essity Aktiebolag (Publ) 12.3.6 Kao Corporation 12.3.7 Daio Paper Corporation 12.3.8 Ontex 12.3.9 Hengan International Group Company Ltd. 12.3.10 Premier Fmcg 12.3.11 Drylock Technologies 12.3.12 Natracare LLC 12.3.13 First Quality Enterprises, Inc. 12.3.14 Bingbing Paper Co. Ltd. 12.4 SME Matrix, 2019 12.4.1 Star 12.4.2 Emerging Companies 12.4.3 Pervasive 12.4.4 Emerging Leaders 12.5 SME Profiles 12.5.1 Diva International Inc. 12.5.2 Premier Care Industries 12.5.3 Lambi 12.5.4 Hygienic Articles 12.5.5 Tzmo Sa 12.5.6 Tosama 12.5.7 Redcliffe Hygiene Private Limited 12.5.8 the Keeper, Inc. 12.5.9 Alyk, Inc 12.5.10 Quanzhou Hengxue Women Sanitary Products Co. Ltd. 12.5.11 Cotton High Tech, S.L. (Cohitech) 12.5.12 Rael Inc 12.5.13 Sirona Hygiene Pvt Ltd. 12.5.14 Sterne 12.5.15 Meluna 13 AppendixFor more information about this report visit https://www.researchandmarkets.com/r/4ybne3Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Semiconductor Intellectual Property Market Research Report by Design IP (Interface IP, Memory IP, and Processor IP), by IP Source (Licensing and Royalty), by IP Core, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19New York, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Semiconductor Intellectual Property Market Research Report by Design IP, by IP Source, by IP Core, by End-User - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993432/?utm_source=GNW The Global Semiconductor Intellectual Property Market is expected to grow from USD 5,374.19 Million in 2019 to USD 8,069.37 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 7.00%. Market Segmentation & Coverage: This research report categorizes the Semiconductor Intellectual Property to forecast the revenues and analyze the trends in each of the following sub-markets: Based on Design IP, the Semiconductor Intellectual Property Market studied across Interface IP, Memory IP, and Processor IP. Based on IP Source, the Semiconductor Intellectual Property Market studied across Licensing and Royalty. Based on IP Core, the Semiconductor Intellectual Property Market studied across Hard IP Core and Soft IP Core. Based on End-User, the Semiconductor Intellectual Property Market studied across Automobile, Computers and Peripherals, Consumer Electronics, and Industrial. Based on Geography, the Semiconductor Intellectual Property Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom. Company Usability Profiles: The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Semiconductor Intellectual Property Market including Achronix Semiconductor, Achronix Semiconductor Corporation, ARM Ltd, Cadence Design Systems Inc., CEVA Inc., Cobham Gaisler AB, Dolphin Integration, Dream Chip Technologies GmbH, eMemory Technology Inc., Eureka Technology, Inc., Faraday Technology Corporation, Fujitsu Ltd, Imagination Technologies Ltd, MediaTek Inc., Mindtree Limited, Open-silicon, Inc., Rambus Incorporated, Semiconductor Manufacturing International Corporation, Synopsys Inc., Transpacket AS, VeriSilicon Holdings Co., Ltd, Wave Computing, Inc., and Xilinx, Inc.. FPNV Positioning Matrix: The FPNV Positioning Matrix evaluates and categorizes the vendors in the Semiconductor Intellectual Property Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape. Competitive Strategic Window: The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth. Cumulative Impact of COVID-19: COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market. The report provides insights on the following pointers: 1\. Market Penetration: Provides comprehensive information on the market offered by the key players 2\. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets 3\. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments 4\. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players 5\. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments The report answers questions such as: 1\. What is the market size and forecast of the Global Semiconductor Intellectual Property Market? 2\. What are the inhibiting factors and impact of COVID-19 shaping the Global Semiconductor Intellectual Property Market during the forecast period? 3\. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Semiconductor Intellectual Property Market? 4\. What is the competitive strategic window for opportunities in the Global Semiconductor Intellectual Property Market? 5\. What are the technology trends and regulatory frameworks in the Global Semiconductor Intellectual Property Market? 6\. What are the modes and strategic moves considered suitable for entering the Global Semiconductor Intellectual Property Market? Read the full report: https://www.reportlinker.com/p05993432/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ CONTACT: Clare: firstname.lastname@example.org US: (339)-368-6001 Intl: +1 339-368-6001
A significant part of the Nagorno-Karabakh region has been reclaimed by Azerbaijan under a peace deal with Armenia that ended six weeks of fierce fighting.
We hereby announce that election of an employee representative to the board of directors of Gabriel Holding A/S was held on 30 November 2020. Sales Supporter in Customer Service, Quinten Van Dalm, has been re-elected as employee representative on Gabriel Holding A/S' board of directors for a 4-year period with appointment immediately after the company's annual general meeting on 10 December 2020. Attachment * Gabriel Holding AS - Announcement no 17 - Election of employee representative for the board of directors
Online reviews are an excellent way for property owners to get feedback on their vacation rentals. Reviews from past guests -- especially five-star ones -- are one of the best ways to attract new renters and keep your rental booked all season. A review aggregator can make a world of difference in your vacation property bookings.
PARIS, Dec 1 (Reuters) - "Chez Francoise" is a discreetly located venue near the French parliament whose visitors' book boasts signatures from former leaders including Nicolas Sarkozy and Francois Hollande. In late September, as a second wave of COVID-19 infection loomed, government scientific advisers wanted new restrictions on bars, restaurants and cafes. Fearing his business would suffer, Pascal Mousset, who owns Chez Francoise and four other restaurants in the French capital, decided to seek help from an old contact.
Angelo Ogbonna has hailed his manager David Moyes for transforming West Ham and taking them to fifth in the Premier League. Goals from the Italian defender and Jarrod Bowen saw the Hammers move to within one point of the Champions League places with a 2-1 win over Aston Villa last night. West Ham rode their luck in the second half and Villa striker Ollie Watkins missed a penalty before having an injury-time equaliser ruled out, after Ogbonna had pushed him into an offside position and the challenge was missed by VAR.
STRATHROY, Ontario, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Eve & Co Incorporated (“Eve & Co”, “we”, “us” or the “Company”) (TSX-V: EVE; OTCQX: EEVVF) is pleased to announce that its wholly-owned subsidiary, Natural MedCo Ltd. (“NMC”), successfully shipped its first order of cannabis-infused bath bombs to the Ontario Cannabis Store (“OCS”) this month. Eve & Co has shipped two of its cannabis-infused bath bomb products, The Boss and The Dreamer. These products are the first of their kind to market as well as the first product launch in the Company’s cannabis 2.0 line of female-focussed products in Ontario.The Eve & Co cannabis-infused bath bombs are manufactured by a woman-led team within the Company’s 1,000,000 square foot greenhouse facility in Strathroy, Ontario. The products are individually hand made with a full spectrum distillate extracted from the Company’s sun-grown cannabis and are formulated to include specific terpene and aromatic properties.The BossThe Boss bath bomb is infused with natural lemon, grapefruit and sweet orange essential oils and is meant to empower you to take on all challenges with exceptional boldness.The DreamerThe Dreamer bath bomb is infused with natural lavender and chamomile essential oils and is meant to calm the soul and soothe the body at the end of a long day.“We couldn’t be more excited to be launching our cannabis-infused bath bomb products in our home province just in time for the holiday season. Our bath bomb production team, endearingly known as our “bombers”, have worked tirelessly to get these wonderful products to market for Ontarians to enjoy, especially as we are all spending more time than ever at home this winter,” said Melinda Rombouts, President and Chief Executive Officer of Eve & Co.ABOUT EVE & CO Eve & Co, through its wholly-owned subsidiary NMC, holds cultivation and processing licences under the Cannabis Act (Canada) for the production and sale of various cannabis products, including dried cannabis, cannabis plants and extraction of cannabis oil and has received its European Union certificate of Good Manufacturing Practice. NMC was Canada’s first female-founded licensed producer of medicinal marijuana and received its cultivation licence from Health Canada in 2016. Eve & Co is led by a team of agricultural experts and has a licensed 1,000,000 square foot greenhouse located in Strathroy, Ontario. The Company’s website can be visited at www.evecannabis.ca.Neither the CSE and TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur, and include, but are not limited to, the production and sale of bath bombs by the Company, whether sales of bath bombs will occur, if any at all, or recur and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's management’s discussion and analysis dated November 26, 2020 (the "MD&A") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. The Company cautions that the list of risks, uncertainties and other factors described in the MD&A is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.For further information, please contact: Melinda Rombouts President and Chief Executive Officer Eve & Co Incorporated Telephone: (855) 628-6337Rory Taylor Interim Chief Financial Officer Eve & Co Incorporated Telephone: (855) 628-6337
Low-Cost Low-Power Sensors and Flexible Network Options Provide Utilities with New Approach to Rapidly Execute Digitization and Safety PlansPORTSMOUTH, N.H., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Senet, Inc., a leading provider of cloud-based software and services platforms that enable global connectivity and on-demand network build-outs for the Internet of Things (IoT), today announced it is collaborating with CNIguard and Semtech Corporation (Nasdaq: SMTC) to deliver natural gas monitoring solutions to utilities across the United States. Through this partnership, the companies are addressing the utility industry’s digitization requirements by providing an intelligent network infrastructure designed to support a massive ecosystem of utility-centric LoRaWAN devices for gas safety and service delivery. Starting with gas safety, the companies are collaborating to introduce a new version of CNIguard’s GasMarshal methane sensor which integrates Semtech’s LoRa® devices and the LoRaWAN® protocol. The CNIguard network-connected gas leak detection solution supports accurate, maintenance-free operation with service level agreements (SLAs) over 10 years due to the market leading power efficiency of its battery-operated devices. CNIguard will also be integrating its solution with Senet’s LoRaWAN network - the largest public, SLA-backed carrier-grade LoRaWAN network in the United States. Offering extensive flexibility to utilities, Senet provides options for public, private and semi-private network deployment and network operation. The low total cost of ownership (TCO) delivered by the efficiencies of devices developed with the LoRaWAN protocol, coupled with flexible network deployment models, are enabling new levels of operational efficiency and rate payer affordability.“We’re excited to be working with Senet and Semtech to develop sensor-enabled devices and solutions that will help modernize critical infrastructure, enhance safety and improve overall operational efficiency for utilities,” said Edward Klinger, CEO at CNIguard. “Our utility customers are investing in the technologies that will enable the next generation of energy systems and we view supporting the LoRaWAN protocol as a critical element of that process.”Executing a collaborative go-to-market strategy, CNIguard, Senet and Semtech are engaged in field trials with large multi-utility service providers to explore use cases focused on improving safety levels and reliability across regional distribution networks. Extending value further, with a Senet network in place for gas leak detection, utilities can easily add network capacity and coverage to enhance operations and expand their service offerings to include other gas safety and service delivery solutions on the same IoT network.“Senet has commercially deployed dense LoRaWAN networks in municipalities across the United States to support AMI for water metering and water management applications, and opportunities in the natural gas market are following close behind,” said Bruce Chatterley, CEO at Senet. “We look forward to a successful partnership with CNIguard in support of this growing market opportunity and are excited to be teamed with Semtech and CNIguard to deliver new levels of commercial and consumer safety through IoT connected solutions.”“Carrier-grade network connectivity from Senet and highly reliable low-cost sensors based on the LoRaWAN protocol from CNIguard provide utilities with new models of control and the ability to drive their vision of automation and digitization faster than ever before,” said Marc Pegulu, Vice President of IoT Product Marketing at Semtech’s Wireless Sensing Business. “With these solutions available today, utilities are in a unique position to become leading adopters of large scale IoT solutions that will have a lasting positive impact on the safety of citizens, the modernization of municipal infrastructure, and resource conservation.”According to the U.S. Energy Information Administration, nearly half of all homes in the United States use natural gas as their primary heat source and, although it may seem rare, the Pipeline and Hazardous Materials Safety Administration reports explosion accidents involving natural gas pipelines occur once every two days. Statistics from NFPA publications and reports from the National Transportation Safety Board (NTSB) show that most major gas incidents in the United States involve some type of leak, resulting in an average of 40 deaths, 140 civilian injuries and over $50 million in direct property damage per year. For utilities, mitigating and ultimately eliminating these incidents and ensuring the safe, efficient, and environmentally sound distribution of natural gas to residential and commercial consumers is of paramount concern. In addition to enhancing consumer safety, these solutions assist utilities in supporting existing and expected legislative regulations focused on gas leak detection and remediation processes.About Senet, Inc. Senet develops cloud-based software and services used by Network Operators, Application Developers, and System Integrators for the on-demand deployment of Internet of Things (IoT) networks. In addition to industrial and commercial applications, Senet has designed smart meter networks for many municipal water utility districts across North America, representing millions of households. With a multi-year head start over competing Low Power Wide Area Network technologies, Senet offers technology in over eighty countries and owns and operates the largest publicly available LoRaWAN network in North America. Our disruptive go-to-market models and critical technical advantages have helped us become a leading connectivity provider with recognized expertise in building and operating global IoT networks. For additional information, visit www.senetco.com.About CNIguard CNIguard is a high technology firm delivering infrastructure protection, public & worker safety and asset management solutions to the energy, electricity, water, transportation and other vital sectors. In an era of Big Data and the Industrial Internet of Things (IIOT), through our SensorCore® platform, CNIguard solutions enable the monetization of data. Our devices that include Sentir (Manhole Monitoring System), GasMarshal (Gas Monitoring System), InDetect (Intrusion Detection System) and OverLine (Overhead Line Monitoring System), are embedded into transmission and distribution networks and comprise diverse sensors in a ruggedized design, with long life battery or power harvesting, and simple, rapid installation. For additional information, visit https://www.cniguard.com/About Semtech Semtech Corporation is a leading supplier of high-performance analog and mixed-signal semiconductors and advanced algorithms for infrastructure, high-end consumer and industrial equipment. Products are designed to benefit the engineering community as well as the global community. The Company is dedicated to reducing the impact it, and its products, have on the environment. Internal green programs seek to reduce waste through material and manufacturing control, use of green technology and designing for resource reduction. Publicly traded since 1967, Semtech is listed on the Nasdaq Global Select Market under the symbol SMTC. For more information, visit www.semtech.com.Senet Contact: Betsey Rogers BridgeView Marketing 603-821-0809 email@example.comCNIguard Contact: Justen Augustine Associate 212-764-0100 firstname.lastname@example.org Semtech Contact: Ronda Grech Semtech Corporation (805) 250-1263 email@example.com
GREENWICH, Conn., Dec. 01, 2020 (GLOBE NEWSWIRE) -- XPO Logistics, Inc. (NYSE: XPO), a leading global provider of transportation and logistics solutions, today announced a companywide shoe drive to benefit the non-profit organization Soles4Souls. During the month of December, XPO employees will collect new or lightly used shoes to help Soles4Souls aid people living below the poverty line. The shoe drive expands on XPO’s support of Soles4Souls, following the company’s donations of supply chain services earlier this year."Today, on Giving Tuesday, we're launching our December shoe drive to help Soles4Souls bring comfort to children and adults in need," said LaQuenta Jacobs, XPO’s chief diversity officer. “We hope that everyone will celebrate this global day of generosity by making a difference in someone’s life through an act of kindness.”To learn more about Souls4Souls or provide support, please visit soles4souls.org.About XPO Logistics XPO Logistics, Inc. (NYSE: XPO) is a top ten global logistics provider of cutting-edge supply chain solutions to the most successful companies in the world. The company operates as a highly integrated network of people, technology and physical assets in 30 countries, with 1,499 locations and approximately 97,000 employees. XPO uses its network to help more than 50,000 customers manage their goods most efficiently throughout their supply chains. XPO's corporate headquarters are in Greenwich, Conn., USA, and its European headquarters are in Lyon, France. xpo.comAbout Soles4Souls Soles4Souls turns unwanted shoes and clothing into opportunity by putting them to good use: providing relief, creating jobs and empowering people to break the cycle of poverty. With locations across three continents, Soles4Souls has distributed more than 50 million pairs of shoes in 129 countries since 2006. soles4souls.orgMedia Contact XPO Logistics, Inc. Joe Checkler +1-203-423-2098 firstname.lastname@example.org
Completion of rolling submission for the BLA expected in 1H21 NDA for umbralisib monotherapy currently under review with the FDA; PDUFA goal date of February 15, 2021 for MZL and June 15, 2021 for FL NEW YORK, Dec. 01, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the Company has initiated a rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of ublituximab, the Company’s investigational glycoengineered anti-CD20 monoclonal antibody, in combination with umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with chronic lymphocytic leukemia (CLL). The U.S. FDA previously granted Fast Track Designation to the combination of ublituximab and umbralisib (U2) for the treatment of adult patients with CLL and Orphan Drug Designation (ODD) covering ublituximab in combination with umbralisib for the treatment of CLL. The Company expects to complete the BLA rolling submission in the first half of 2021.Michael S. Weiss, Executive Chairman and Chief Executive Officer of TG Therapeutics stated, “The initiation of a BLA submission for ublituximab in combination with umbralisib is an important milestone for us, and one that brings us one step closer to our goal of developing combination therapies for patients in need. This application, as well as the recently granted Fast Track Designation, is supported by the UNITY-CLL Phase 3 trial which met its primary endpoint of improvement in progression-free survival compared to obinutuzumab plus chlorambucil and will be presented in an oral presentation at the 2020 American Society of Hematology (ASH) annual meeting beginning this weekend.” Mr. Weiss continued, “I want to thank the patients, caregivers and research teams who participated in our clinical trials and helped to advance the U2 combination to this stage. We believe, if approved, U2 has the potential to become an important treatment option to both front line and relapsed/refractory patients with CLL.” The Company has previously submitted a New Drug Application (NDA) to the FDA for umbralisib to treat relapsed/refractory marginal zone lymphoma (MZL) and follicular lymphoma (FL) and the FDA has granted Prescription Drug User Fee Act (PDUFA) goal dates of February 15, 2021 for MZL and June 15, 2021 for FL.ABOUT UNITY-CLL PHASE 3 TRIAL UNITY-CLL is a global Phase 3 randomized controlled clinical trial comparing the combination of ublituximab plus umbralisib, or U2, to an active control arm of obinutuzumab plus chlorambucil in patients with both treatment-naïve and relapsed or refractory chronic lymphocytic leukemia (CLL). The trial randomized patients into four treatment arms: ublituximab single agent, umbralisib single agent, ublituximab plus umbralisib, and an active control arm of obinutuzumab plus chlorambucil. A prespecified analysis was conducted to assess the contribution of ublituximab and umbralisib in the U2 combination arm and allowed for the termination of the single agent arms. Accordingly, the UNITY-CLL Phase 3 trial continued enrollment in a 1:1 ratio into the two combination arms: the investigational arm of U2 and the control arm of obinutuzumab plus chlorambucil. Approximately 420 subjects enrolled to the two combination arms and approximately 60% of patients were treatment-naïve and 40% were relapsed or refractory. The primary endpoint for this study was superior progression-free survival (PFS) for the U2 combination compared to the control arm to support the submission for full approval of the U2 combination in CLL. Positive topline results from this trial were announced in May 2020. The UNITY-CLL Phase 3 trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). ABOUT CHRONIC LYMPHOCYTIC LEUKEMIA Chronic lymphocytic leukemia (CLL) is the most common type of adult leukemia, and in 2020 it is estimated there will be more than 20,000 new cases of CLL diagnosed in the United States1. Although signs of CLL may disappear for a period of time after initial treatment, the disease is considered incurable and many people will require additional treatment due to the return of malignant cells. ABOUT FAST TRACK Fast Track is a program designed to expedite the development and review of drugs that treat serious conditions and that demonstrate the potential to address an unmet medical need. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy that may be potentially better than available therapy. A drug that receives Fast Track designation is eligible for more frequent interactions with the FDA, priority review if relevant criteria are met, and rolling submission of the Biologics License Application or New Drug Application.ABOUT ORPHAN DRUG DESIGNATION Orphan drug designation is granted by the FDA to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnosis or prevention of rare diseases/disorders that affect fewer than 200,000 people in the U.S. Orphan drug designation provides certain incentives which may include tax credits towards the cost of clinical trials and prescription drug user fee waivers. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity.ABOUT TG THERAPEUTICS, INC. TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is in late-stage clinical development with two investigational compounds, ublituximab and umbralisib, the combination of which is referred to as “U2”, targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. Umbralisib (TGR-1202) is an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon. Umbralisib is currently under review by the U.S. Food and Drug Administration (FDA) for accelerated approval as a treatment for patients with previously treated marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen or follicular lymphoma (FL) who have received at least two prior systemic therapies. The Company also has a fully enrolled Phase 3 clinical trial evaluating U2 in patients with treatment naïve and relapsed/refractory chronic lymphocytic leukemia (CLL), and two fully enrolled identical Phase 3 trials evaluating ublituximab monotherapy in patients with relapsing forms of multiple sclerosis (RMS). Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.__________________________________________________1 Cancer Stat Facts: Leukemia – Chronic Lymphocytic Leukemia https://seer.cancer.gov/statfacts/html/clyl.html Cautionary Statement This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. In addition to the risk factors identified from time to time in our reports filed with the Securities and Exchange Commission, factors that could cause our actual results to differ materially are the following: our ability to successfully and cost effectively complete preclinical and clinical trials; the risk that the Company will not complete its planned U.S. regulatory submissions for ublituximab in combination with umbralisib in patients with CLL in the projected timeframe or at all; the risk that the FDA will not accept the BLA submission of ublituximab in combination with umbralisib in patients with CLL; the risk that the FDA will not approve the pending NDA for umbralisib or the BLA for ublituximab in combination with umbralisib; the risk that safety issues or trends will be observed in the UNITY-CLL study when the full safety dataset is available or in any other on-going studies that prevent approval of either ublituximab and/or umbralisib; the risk that our product candidates, including ublituximab and umbralisib, will not be commercially successful if approved; the risk that the differentiated tolerability profile for umbralisib previously observed in clinical trials will not be reproduced in the UNITY-CLL trial or any other on-going studies; and the risk that we are not able to achieve the clinical trial and regulatory milestones we project, including the risk that the evolving and unpredictable COVID-19 pandemic delays achievement of those milestones. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. CONTACT:Jenna Bosco Senior Vice President, Corporate Communications TG Therapeutics, Inc. Telephone: 212.554.4351 Email: email@example.com
VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Abacus Mining & Exploration Corporation (“Abacus” or the “Company”) (TSXV: AME) is pleased to announce final results from a program of ground IP geophysics at Jersey Valley, within the Battle Mountain trend of north-central Nevada. The program was successful in extending known IP targets that based on past drilling are demonstratively gold and silver bearing. A total of 44 anomalous IP target areas were defined by the survey, grouped into five separate ENE trending zones, four of which are open in at least one direction. All targets were ranked as first, second and third priority, based on a combination of strength, size, depth and geophysical signature.The survey was designed to detect low to moderately conductive and moderately chargeable zones that might indicate disseminated sulphides around an intrusive stock or along a fault zone. Three zones have signatures characteristic of epithermal precious metal mineralization and two others have signatures associated with gold skarns. The property lies within an active hydrothermal environment, with an operating geothermal power plant on the claim group.The high-resolution Time Domain Induced Polarization survey totaled 14 line-kilometres and was designed to bracket four historic lines of IP done by a previous operator in 2005. The historic survey was laid out to target a depth of approximately 200 metres, while the new survey was designed to penetrated depths of over 400 metres. Results of both surveys are currently being merged.JV-1 and JV-2 are the two main IP target zones, and both extend the anomalies 500 metres from the historic IP survey. They lie on either side of a fault thought to be the conduit for mineralizing fluids feeding epithermal mineralization. JV-1 can be traced for at least 700 m and JV-2 for at least 900 m. A new map showing these zones will be posted on the Company website.Three historic diamond drill holes appear to have just grazed JV-1 and JV-2, but past drilling was neither extensive enough, deep enough nor optimally placed to adequately test the targets. Both JV-1 and JV-2 remain essentially untested, and the Company intends to undertake a drilling program early in the new year once permits are in hand.Historic drill hole 06JC014C was collared within the northeast part of JV-2, but it tested a weaker anomaly and missed a stronger, slightly deeper anomaly. Despite this, the hole intersected 1.18 g/t silver over 13.1 m near the top and then 0.19 g/t gold over 13.4 m within a slightly wider intercept of 2.36 g/t Ag over 16.5 m near the end of the hole.Hole 06JC015C was collared 200 m west of 06JC014C and it also intercepted JV-2. It returned 0.18 g/t gold and 3.6 g/t silver over 6.09 m part way through the hole and then 1.58 g/t gold over 1.52 m near the end of the hole. This upper intercept is within a weaker anomaly, and the lower seems to have just hit the top of a much better target.Likewise, the northeast edge of JV-2 was intersected by historic drill hole 06JC017C, which assayed narrow zones of anomalous gold and silver throughout, and then 0.18 g/t gold and 2.98 g/t Ag over 29.87 m. at the end of the hole. This hole also grazed the edge of a second order target.All three holes have disseminated sulphides throughout, including pyrite and stibnite. All contain anomalous gold and silver, along with a suite of other elements typical of these precious metal bearing systems. Note that all intercepts are down hole lengths, as insufficient drilling was done to determine true widths. Note further that these results are historic in nature and although the author was not involved in the original work, proper industry standard sampling and data verification procedures appear to have been followed.Two additional IP zones have the signature of skarns related to an intrusion along the southern claim boundary, and the historic IP did not cover this part of the claims. Zone JV-4 has been partially intersected by several historic drill holes containing anomalous gold and silver, and these skarns are secondary targets to the epithermal target zones.The Jersey Valley property is prospective for epithermal precious metal mineralization, in an active hydrothermal environment, similar to the Taupo volcanic zone in New Zealand. The project is within the Battle Mountain trend of north-central Nevada in close proximity to both the Phoenix/Fortitude mine complex (a gold skarn with approximately 14 Moz gold plus significant Ag and Cu past production and a proposed mine life to 2063) and the Cove/McCoy Mine (a Carlin-type gold deposit with 3.4 Moz gold and 110 Moz Ag past production). Data is from the Newmont Mines and Premier Gold Mines websites. The reader is cautioned that the mineralization hosted on nearby properties is not necessarily indicative of mineralization hosted on the Company’s Jersey Valley gold property. The Jersey Valley property has a well-maintained sealed road running through it, which provides access to a 15 MW geothermal power plant located on the edge of the claim group.The Company also has additional properties of merit in Nevada. The Willow and adjacent Nev-Lorraine copper-molybdenum properties are in the Yerington copper camp, southeast of Reno. Drilling by the Company in 2018 intersected a key intrusive rock unit on Willow that hosts all known porphyry Cu-Mo deposits at Yerington. This rock unit was not previously known to exist on the Company’s property, and it represents a significant new discovery. The target is large and robust, and it remains essentially untested.In addition, Abacus holds a 20% ownership interest in the Ajax copper-gold project, located near Kamloops, British Columbia., which is managed by base metal major KGHM Polska Miedź S.A., who hold the remaining 80%. The Ajax Project contains significant quantities of copper and gold, within a NI 43-101 Proven and Probable Mineral Reserve of 426 Mt at 0.29% Cu, 0.19 g/t Au and 0.39 g/t Ag. Contained metal is in the order of 2.7 Bil lbs Cu, 2.6 Moz Au and 5.3 Moz Ag*.The technical information in this news release has been reviewed and approved by Paul G. Anderson, M.Sc., P.Geo., a Qualified Person within the meaning of National Instrument 43-101.* Wardrop Engineering Inc. 2012. Ajax Copper/Gold Project, Kamloops, British Columbia – Feasibility Study Technical Report. Doc. No. 1054610300-REP-R0004-02. January 2012.On Behalf of the Board, ABACUS MINING & EXPLORATION CORPORATIONPaul G. Anderson, P.Geo. President and COOAbout Abacus Abacus is a mineral exploration and mine development company currently focused on its optioned Willow copper-gold property located near Yerington, Nevada in which it can acquire up to a 75% ownership interest, and the contiguous Nev-Lorraine claims subject to a ten-year lease agreement. Abacus also holds a 15-year lease on the Jersey Valley gold property, near Battle Mt., Nevada. The Company’s main asset is a 20% ownership interest, together with KGHM Polska Meidz S.A. (80%), in the proposed copper-gold Ajax Mine located southwest of Kamloops, B.C., which has undergone a joint provincial and federal environmental assessment process. On December 14, 2017, a decision was made by the B.C. Minister of Environment and Climate Change Strategy and the Minister of Energy, Mines and Petroleum resources to decline to issue an environmental assessment certificate for the Project. For the latest reports and information on Abacus’ projects, please refer to the Company’s website at www.amemining.com.Forward-Looking Information This release includes certain statements that are deemed “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that Abacus expects to occur, are forward-looking statements. Forward- looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include changes to commodity prices, mine and metallurgical recovery, operating and capital costs, foreign exchange rates, ability to obtain required permits on a timely basis, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward- looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. CONTACT: Tel: 604.682.0301 email: firstname.lastname@example.org website: www.amemining.com
A potential coronavirus vaccine isn't the only promising pipeline candidate for this small-cap biotech.
ROCKVILLE, Md. and CHESTERBROOK, Pa., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to study the use of CERC-803 to treat Leukocyte Adhesion Deficiency Type II (LAD II). The company plans to initiate a pivotal trial of CERC-803 in LAD-II (SLC35C1-CDG) by the first half of 2021 and anticipates topline data in the second half of 2021. “There are currently no FDA-approved therapies for patients suffering from LAD-II” said H. Jeffrey Wilkins, MD, Chief Medical Officer of Cerecor. “LAD-II is caused by genetic mutations that result in deficiency in expression of surface adhesion molecule selectin, leading to defective leukocyte functions. This is a pediatric disease with the first symptoms appearing in infancy with recurrent bacterial infections, growth retardation, facial dysmorphism, and severe intellectual deficit as they continue to grow. We are excited to advance this program into the clinic.”The FDA granted Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to CERC-803, thus potentially qualifying the Company to receive a Priority Review Voucher (PRV) upon approval of a new drug application (NDA).About CERC-800s CERC-801, CERC-802 and CERC-803 are monosaccharide therapies with known therapeutic utility for the treatment of select congenital disorders of glycosylation (CDGs). Oral administration at therapeutic doses of CERC-801, CERC-802, and CERC-803 replenishes critical metabolic intermediates that are reduced or absent due to genetic mutation, overcoming single enzyme defects in respective CDGs to support glycoprotein synthesis, maintenance and function.About Cerecor Cerecor is a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for rare and orphan diseases. The company is advancing its clinical-stage pipeline of innovative therapies that address unmet patient needs within rare and orphan diseases. The company's rare disease pipeline includes CERC-801, CERC-802 and CERC-803 (CERC-800 compounds), which are therapies for inherited metabolic disorders known as congenital disorders of glycosylation. The FDA granted RPDD and ODD to all three CERC-800 compounds, thus potentially qualifying the Company to receive a PRV upon approval of each NDA. The company is also developing CERC-002, CERC-006 and CERC-007. CERC-002 is an anti-LIGHT monoclonal antibody being developed for the treatment of severe pediatric-onset Crohn's disease, and is also being studied for COVID-19 acute respiratory distress syndrome. CERC-006 is a dual mTOR inhibitor being developed for the treatment of complex lymphatic malformations and has been granted ODD and RPDD by the FDA, thus potentially qualifying the company to receive a fourth PRV upon approval of an NDA. CERC-007 is an anti-IL-18 monoclonal antibody being developed for the treatment of autoimmune inflammatory diseases such as Still’s disease and multiple myeloma. For more information about Cerecor, please visit www.cerecor.com.Forward-Looking Statements This press release may include forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to significant risks and uncertainties that are subject to change based on various factors (many of which are beyond Cerecor’s control), which could cause actual results to differ from the forward-looking statements. Such statements may include, without limitation, statements with respect to Cerecor’s plans, objectives, projections, expectations and intentions and other statements identified by words such as “projects,” “may,” “might,” “will,” “could,” “would,” “should,” “continue,” “seeks,” “aims,” “predicts,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” or similar expressions (including their use in the negative), or by discussions of future matters such as: the development of product candidates or products; timing and success of trial results and regulatory review; potential attributes and benefits of product candidates; and other statements that are not historical. These statements are based upon the current beliefs and expectations of Cerecor’s management but are subject to significant risks and uncertainties, including: drug development costs, timing and other risks, including reliance on investigators and enrollment of patients in clinical trials, which might be slowed by the COVID-19 pandemic; regulatory risks; Cerecor's cash position and the potential need for it to raise additional capital; general economic and market risks and uncertainties, including those caused by the COVID-19 pandemic; and those other risks detailed in Cerecor’s filings with the Securities and Exchange Commission. Actual results may differ from those set forth in the forward-looking statements. Except as required by applicable law, Cerecor expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Cerecor’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.For media and investor inquiriesJames Harrell Investor Relations Chief Commercial Officer Cerecor Inc. email@example.com 623.439.2220 office
President-elect Joe Biden's promise to end U.S. fossil fuel subsidies worth billions of dollars a year for drillers and miners could be hard to keep due to resistance from lawmakers in a narrowly divided Congress, including from within his own party. The challenge reflects just one of the obstacles that Biden will need to overcome as he seeks to usher in sweeping measures to combat climate change and transform the nation’s economy to net-zero emissions within three decades. Biden has said axing fossil fuel subsidies will generate money to help pay for his broader $2 trillion climate plan.
Achilles Therapeutics Appoints Robert Coutts as Chief Financial OfficerStevenage, UK 1 December 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat multiple types of solid tumours, today announced the appointment of Robert Coutts as Chief Financial Officer. Robert has served as Finance Director at Achilles since the Company’s formation in 2017.“Robert has been part of the Achilles team since the beginning and I’m delighted to welcome him to his new role,” said Dr. Iraj Ali, CEO of Achilles Therapeutics. "Robert has deep expertise in building and developing operating businesses. His experience, leadership and commitment to the Company will be integral as our potentially transformative precision TIL therapy progresses in the clinic in multiple solid tumor indications.”“I have been fortunate enough to be a part of the Company's evolution over the last few years, and I look forward to continuing to support Iraj, the management team and Board in our efforts to develop much needed novel cancer therapies for patients,” said Robert Coutts, CFO of Achilles Therapeutics. “As the Company continues to advance its pipeline, the finance function will be an important strategic partner across the Company, including research and development, manufacturing and clinical operations."Prior to joining Achilles, Robert worked for Syncona Ltd leading the finance functions of new entities within its life science portfolio. He previously served in roles of increasing responsibility at the Wellcome Trust. Robert qualified as a chartered accountant with KPMG where he spent time in both their Audit and Transactions & Restructuring teams. He has an MSc in Management from Cass Business School and a BA in Politics, Philosophy and Economics from Oxford University.– Ends –Notes for Editors:About Achilles TherapeuticsAchilles Therapeutics is a clinical stage, biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic malignant melanoma. Achilles uses DNA sequencing data from each patient, together with the proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop personalised T cell-based therapies specifically targeting those clonal neoantigens.For further information please visit the Company’s website at: www.achillestx.com. Further information:Achilles Therapeutics Dr Iraj Ali – Chief Executive Officer +44 (0)1438 906 906 firstname.lastname@example.orgJulia Wilson – Head of Communications +44 (0)7818 430877 email@example.comConsilium Strategic Communications Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner +44 (0) 203 709 5000 firstname.lastname@example.org